PREVENT: Preeclampsia Detection - Verifying a Novel Rapid Test

Mathias Wipf of MOMM Diagnostics GmbH will improve their préXclude test to better enable its use in low- and middle-income countries (LMICs) as an affordable point-of-care diagnostic platform for prediction and detection of preeclampsia early in pregnancy. The existing test is contained in a single-use cartridge connected to an inexpensive handheld reader. It is based on an electrochemical enzyme-linked lateral flow immunoassay that quantifies the levels and ratio of two key preeclampsia biomarker proteins, sFlt1 and PIGF, in whole blood from a finger prick. Multiple aspects of the test will be improved to enhance usability and analytical performance, with the goal of developing a prototype platform that meets a target product profile appropriate for LMIC settings.